| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 |
| Sales | 0 | 580 | 70 | 0 | 0 |
| Sales Growth | -100.00% | +728.56% | unch | unch | -100.00% |
| Net Income | -14,080 | -44,540 | -21,670 | -24,580 | -122,310 |
| Net Income Growth | +68.39% | -105.54% | +11.84% | +79.90% | -2,667.19% |
Ernexa Therapeutics Inc (ERNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Ernexa Therapeutics is developing cell therapies for the treatment of advanced cancer and autoimmune disease. Ernexa Therapeutics, formerly known as Eterna Therapeutics, is based in CAMBRIDGE, Mass.
Fiscal Year End Date: 12/31